This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- CAPLYTA is indicated in adults for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate.1
- Suppes et al (2023)2 conducted a 6-week, phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of CAPLYTA as adjunctive treatment to lithium or valproate in patients with major depressive episodes (MDEs) associated with bipolar I or bipolar II disorder.
- An improvement in MADRS total score was observed in CAPLYTA 42 mg adjunctive to lithium or valproate compared to placebo with lithium or valproate at approximately day 15.
- At day 43, CAPLYTA 42 mg adjunctive to lithium or valproate showed a statistically significant improvement in MADRS total score compared to placebo adjunctive to lithium or valproate, with an LSMD of -2.4 (95% CI: -4.42 to -0.37; effect size=-0.27; P=0.021).
- Calabrese et al (2021)3 conducted a 6-week, phase 3, randomized, double-blind, placebo-controlled, multinational study to evaluate the efficacy and safety of CAPLYTA in patients with MDEs associated with bipolar I or bipolar II disorder.
- An improvement in MADRS total score compared to placebo was observed at day 8, with an LSMD of -1.3 (95% CI: -2.27 to -0.31).4
- At day 43, CAPLYTA 42 mg showed a statistically significant improvement in MADRS total score compared to placebo, with an LSMD of -4.6 (95% CI: -6.34 to -2.83; effect size=-0.56; P<0.0001).3
BACKGROUND
The Food and Drud Administration (FDA) approval of CAPLYTA was based upon positive results of two short-term (6-week), placebo-controlled trials in patients with bipolar depression. In one study, CAPLYTA was given as monotherapy and, in the second study, CAPLYTA was given as adjunctive therapy with lithium or valproate.2,3
CLINICAL DATA
Suppes et al (2023)2 conducted a phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of CAPLYTA as adjunctive treatment to lithium or valproate in patients with MDEs associated with bipolar I or bipolar II disorder. Patients were randomized (1:1:1) to receive lumateperone 28 mg (n=176), CAPLYTA 42 mg (n=177), or placebo (n=175) for 6 weeks; this was followed by a 2-week safety follow-up period. The primary efficacy endpoint was the change from baseline to day 43 in MADRS total score.
- An improvement in MADRS total score was observed in CAPLYTA 42 mg adjunctive to lithium or valproate compared to placebo with lithium or valproate at approximately day 15.
- At day 43, CAPLYTA 42 mg adjunctive to lithium or valproate showed a statistically significant improvement in MADRS total score compared to placebo adjunctive to lithium or valproate, with an LSMD of -2.4 (95% CI: -4.42 to -0.37; effect size=-0.27; P=0.021).
Calabrese et al (2021)3 conducted a phase 3, randomized, double-blind, placebo-controlled, multinational study to evaluate the efficacy and safety of CAPLYTA in patients with MDEs associated with bipolar I or bipolar II disorder. Patients were randomized (1:1) to receive either CAPLYTA 42 mg (n=188) or placebo (n=189) for 6 weeks; this was followed by a 2-week safety follow-up period. The primary efficacy endpoint was the change from baseline to day 43 in MADRS total score.
- An improvement in MADRS total score compared to placebo was observed at day 8, with an LSMD of -1.3 (95% CI: -2.27 to -0.31).4
- At day 43, CAPLYTA 42 mg showed a statistically significant improvement in MADRS total score compared to placebo, with an LSMD of -4.6 (95% CI: -6.34 to -2.83; effect size=-0.56; P<0.0001).3
Literature Search
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 13 October 2026.
| 1 | CAPLYTA (lumateperone) [Prescribing Information]. Titusville, NJ: Intra-Cellular Therapies, Inc; https://www.intracellulartherapies.com/docs/caplyta_pi.pdf |
| 2 | Suppes T, Durgam S, Kozauer SG, et al. Adjunctive lumateperone (ITI‐007) in the treatment of bipolar depression: results from a randomized placebo‐controlled clinical trial. Bipolar Disord. 2023;25(6):478-488. |
| 3 | Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178(12):1098-1106. |
| 4 | Data on File. CAPLYTA. Clinical Study Report of Study 404. Intra-Cellular Therapies, Inc; 2020. |